Principaux documents

Voir toute la documentation

P1793

Pimozide

Name: Pimozide
Brand: SIGMA

≥98% (TLC), powder, D₂ dopamine receptor antagonist

Synonyme(s) :

1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :

C₂₈H₂₉F₂N₃O

Numéro CAS:

2062-78-4

Poids moléculaire :

461.55

NACRES:

NA.77

PubChem Substance ID:

24277923

UNSPSC Code:

12352200

EC Number:

218-171-7

MDL number:

MFCD00055081

Form:

powder

Quality level:

200

Service technique

Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.

Laissez-nous vous aider

Propriétés

Nom du produit

Pimozide,

form

powder

Quality Level

200

solubility

DMSO: 18 mg/mL(lit.), chloroform: 5 mg/mL, H₂O: insoluble(lit.)

originator

Teva

storage temp.

2-8°C

SMILES string

Fc1ccc(cc1)C(CCCN2CCC(CC2)N3C(=O)Nc4ccccc34)c5ccc(F)cc5

InChI

1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)

InChI key

YVUQSNJEYSNKRX-UHFFFAOYSA-N

Gene Information

human ... ABCB1(5243), CACNA1G(8913), CYP3A4(1576), DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816), HTR2A(3356), HTR7(3363), KCNH1(3756), KCNH2(3757), OPRD1(4985)
mouse ... Abcb1a(18671), Abcb1b(18669)
rat ... Scnn1g(24768)

Description

Biochem/physiol Actions

D₂ dopamine receptor antagonist; binds with high affinity to the cloned 5-HT₇ receptor; Ca²⁺ channel antagonist; antipsychotic

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Cyclic Nucleotide-Gated (CNG) and Hyperpolarization Activated Cyclic Nucleotide-Gated (HCN) Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Teva. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under

pictograms

GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells.

Junjun Chen et al.

Chemistry & biology, 18(11), 1390-1400 (2011-11-29)

Ubiquitin-specific proteases (USPs) have in recent years emerged as a promising therapeutic target class. We identified selective small-molecule inhibitors against a deubiquitinase complex, the human USP1/UAF1, through quantitative high throughput screening (qHTS) of a collection of bioactive molecules. The top

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.

Holger H H Erb et al.

PloS one, 15(8), e0237248-e0237248 (2020-08-14)

Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour progression and

Pimozide for tics in Tourette's syndrome.

Tamara Pringsheim et al.

The Cochrane database of systematic reviews, (2)(2), CD006996-CD006996 (2009-04-17)

Neuroleptic drugs with potent D-2 receptor blocking properties have been the traditional treatment for tics caused by Tourette Syndrome. Pimozide is the most studied of these. Use of these medications is declining because of concerns about side effects, and new

Afficher tous les articles scientifiques apparentés